Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Completed
- Conditions
- Hepatocellular CarcinomaMetastasesCholangiocarcinomaStereotactic Body Radiotherapy
- Interventions
- Other: Measuring liver function by PET/CT
- Registration Number
- NCT01213758
- Lead Sponsor
- University of Aarhus
- Brief Summary
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- liver tumor
- referred for stereotactic radiation therapy
- age > 18 years
Read More
Exclusion Criteria
- Impaired kidney function
- Pregnancy
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Liver tumors Measuring liver function by PET/CT Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
- Primary Outcome Measures
Name Time Method Uptake of FDGal Before, 1 month and 3 months after stereotactic radiotherapy Volumetric uptake of FDGal can be measured is measured by PET/CT
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Aarhus University Hospital
🇩🇰Aarhus C, Denmark